Metabolic Outcomes Beyond Weight Loss The clinical trials measured several metabolic parameters beyond body weight: Glycemic control (Type 2 diabetes trial Rosenstock et al., 2023) A separate Phase 2 trial in participants with type 2 diabetes (published in The Lancet ) demonstrated significant improvements in glucose metabolism
Our programs may include GLP-1 or GLP-1/GIP receptor agonist therapy (such as semaglutide or tirzepatide), metabolic testing, body composition analysis, nutritional guidance, and ongoing monitoring to ensure safe, effective, and lasting results
1 Tolerability Semaglutide is generally well tolerated with similar dropout rates when compared with placebo, although it may be less well tolerated than dulaglutide (Trulicity)
These therapies are holistic in nature and enhance wellness as well as body composition
By opting for a semaglutide weight loss program, experience the benefits that go beyond what Ozempic offers, ensuring targeted weight reduction with consistent monitoring